TherapeuticsMD Inc. (NASDAQ:TXMD) stock is down -3.91% to close at $2.70 on Wednesday, 01/22/20. TXMD stock is lower by -$0.11 from the previous closing price of $2.81 on volume of 4522391 shares. In the meantime, TXMD was trading in the Healthcare sector, the stock is trading -55.67% low as compared to its 52-week high price and 48.35% high as compared to its 52-week low price. Of example, both the price and the high and low measurements of 52 weeks will give you a clear image for determining the price track. The firm has a Weighted Alpha of -52.3. A positive weighted alpha shows that over the past year the stock has risen. A negative means that over the same period the stock is down.What do the Analysts Think?
Over the last 12 months, TherapeuticsMD Inc. (TXMD) stock has fallen by -47.47 percent, and Wall Street analysts’ average rating is a Buy. This suggests investors foresee the inventory in the next 12 months to benefit 69.8%.
Estimates of future earnings are probably the most important feedback when attempting to evaluate a company. Analysts can then use cash flow analysis to approximate fair value for a company by placing estimates on a company’s earnings for certain periods. In case of TherapeuticsMD Inc. (TXMD), the Consensus Average Estimate of EPS for fiscal year 12/2019 according to 6 analysts is at -$0.69 per share. The high EPS estimate is -$0.65 per share and the low estimate is -$0.79 per share. The Average estimate indicates the -16.95% growth as compared to the prior year estimated EPS of -$0.59 per share.
TherapeuticsMD Inc. also currently has an EPS Growth of -57.50 percent for current year, showing analysts have bearish about their potential for near-term earnings. EPS is expected to reach 19.50 percent over the next five years, while EPS growth was -21.50 percent over the past five years, along with sales growth of 12.90 percent over the past five years. Next year’s EPS growth is estimated at 23.30%.
The performance of the stocks typically measures, how much a stock gain or lose its value during different time spans. TherapeuticsMD Inc. (NASDAQ:TXMD) has achieved around 16.38% in the last 30 days and around -28.95% over the last three months. The stock exposed return of -30.79% over the period of last 5 years and recorded return of 10.20% over a week. In the last 6 months, the stock has been observed at 25.58% return.Tracking the Profitability and Valuation Ratios
The organization reported a 88.70 percent Gross Margin. The profit margin ratio, also referred to as the revenue ratio or gross profit ratio, is a productivity equation that dealings the amount of net income gained with each dollar in revenues produced by contrasting the company’s net income and net sales. The higher ratio means the more profit and vice versa.
As of the last trading session the stock has achieved a market cap of $784.49M. Market capitalization is the cumulative dollar value of all of a company’s outstanding shares and is used to quantify businesses and consider their overall market value. The stock has attained Price-to-sales ratio of 20.22 replicates the cost to be found on sales by the market.How Insiders are Trading the Stock?
Milligan John C.K. IV, President/Secretary of TherapeuticsMD Inc. (TXMD) bought 72,000 shares of firm against total value of $198,000 at the rate of $2.75 on Oct 25. Bernick Brian, Director of TherapeuticsMD Inc. (TXMD) bought 36,000 shares of firm against total value of $99,000 at the rate of $2.75 on Oct 25. Milligan John C.K. IV, President/Secretary of TherapeuticsMD Inc. bought 72,000 shares of firm against total value of $198,000 at the rate of $2.75 on Oct 25. Mostly, the investors and traders are looking for stocks with the high ownership of company’s management because they think that when the company’s management is the major shareholder of a firm, the management will run the business for itself and they will never act those activities which are against their interests and they will always try to create shareholder value in the long-term. Currently, 7.40% of TherapeuticsMD Inc.‘s shares possessed by insiders, while 64.40% shares possessed by financial institutions.